Clinical Trials
17 trialsNCT02143401 2024-11-22
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT01531361 2021-01-22
Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00095459 2019-12-17
BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00610246 2019-02-15
A Study of Radiation With Sorafenib in Advanced Cancer
University Health Network, Toronto
Phase 1 Completed
NCT02636426 2018-10-22
SOPRANO
Amsterdam UMC, location VUmc
Phase 1 Completed
NCT00811993 2016-11-02
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Terminated
NCT01683149 2016-03-04
Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01585870 2015-10-27
Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination
Bayer
Phase 1 Completed
NCT00259129 2014-11-13
Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients
Bayer
Phase 1 Completed
NCT00606125 2014-06-23
Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors
Bayer
Phase 1 Completed
NCT00398814 2014-02-19
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
AEterna Zentaris
Phase 1 Completed
NCT00827177 2014-01-24
Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Completed
NCT00562913 2013-11-26
Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin
Bayer
Phase 1 Completed
NCT01069328 2013-11-13
Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
Bayer
Phase 1 Completed
NCT00562523 2013-05-23
Sorafenib/Docetaxel Dose Escalation Trial
Bayer
Phase 1 Completed
NCT00613145 2013-02-04
Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed
NCT00788099 2011-06-07
Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas
PharmaMar
Phase 1 Completed